IMMUNE STATUS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
Keywords:
benign prostatic hyperplasia, immune status, adenomectomy, cellular immunity, inflammation.Abstract
The purpose of the study was to conduct a comparative analysis of the immune status of patients with benign prostatic hyperplasia (BPH) after various surgical interventions: endoscopic ablation of the prostate (EAP), transurethral resection of the prostate (TUR) and traditional adenomectomy. Eighty patients were included in the study: 20 underwent EAP, 20 underwent TUR, and 40 underwent traditional adenomectomy. The indices of cellular and humoral immunity in the preoperative and postoperative periods were studied. Differences in the immune response of the organism depending on the applied method of treatment were revealed.
References
Ahmed R., Hamdy O., Awad R. M. Diagnostic efficacy of systemic immune-inflammation biomarkers in benign prostatic hyperplasia using receiver operating characteristic and artificial neural network //Scientific Reports. – 2023. – Vol. 13. – No. 1. – P. 14801.
Anikhovskaya I. A., Salakhov I. M., Yakovlev M. Yu. A method of diagnostics of latent diseases based on indicators of systemic endotoxinemia. - 2017.
Dzhaparov J. T. et al. Benign prostatic hyperplasia in combination with chronic calculous prostatitis (literature review) //Vestnik Kyrgyz-Russian Slavic University. - 2017. - Vol. 17. - No. 10. - P. 26-28.
Efimova O. A. Analysis of blood serum antioxidant activity in prostate pathologies: dis. - Siberian Federal University, 2018.
Huang T. R. et al. Differential research of inflammatory and related mediators in BPH, histological prostatitis and PCa //Andrologia. – 2018. – Vol. 50. – No. 4. – P. e12974.
Meng Y. et al. The inflammation patterns of different inflammatory cells in histological structures of hyperplasic prostatic tissues //Translational Andrology and Urology. – 2020. – Vol. 9. – No. 4. – P. 1639.
Nitkin D. M. M., Miloshevsky P. V., Juraga T. M. Factors of progression of benign prostatic hyperplasia // Treatment of women with chronic pelvic pain syndrome: our experience. - 2019.
Sanaei M. J. et al. Comparing the frequency of CD33+ pSTAT3+ myeloid-derived suppressor cells and IL-17+ lymphocytes in patients with prostate cancer and benign prostatic hyperplasia //Cell Biology International. – 2021. – Vol. 45. – No. 10. – P. 2086-2095.
Tolegenov E. B. et al. Risk factors of complications after open adenomectomy for benign prostatic hyperplasia in a patient with diabetes // Bulletin of the Kazakh National Medical University. - 2021. - No. 3. - P. 166-169.
Wang S. et al. The values of systemic Immune-inflammation index and neutrophil–lymphocyte ratio in the localized prostate cancer and benign prostate hyperplasia: a retrospective clinical study //Frontiers in Oncology. – 2022. – Vol. 11. – P. 812319.
